Technical Data
Platelet Derived Growth Factor BB, Recombinant, Mouse (PDGF-BB)
Molecular Biology Storage: -20CShipping: Blue Ice
Recombinant Mouse PDGF-BB is a homodimeric, non-glycosylated, polypeptide chain containing 109 amino acids and having a molecular mass of 25kD.

PDGF is a mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication.The synthesis of PDGF can be induced by Interleukin-1, Interleukin-6, TNF-alpha, TGF-beta and EGF.

Amino Acid Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ser-Leu-Gly-Ser.

Biological Activity:
The biological activity is determined by the dose-dependant stimulation of the proliferation of human umbelical vein endothelial cells (HUVEC) using a concentration range of less than 1.6ng/ml.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm using an extinction coefficient of 0.48 for a 0.1% solution
2. Analysis by RP-HPLC, using a standard solution of PDGF-BB as a reference standard

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile 100mM acetic acid, 0.1% BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
Source: E. coli
Purity: 95% as determined by RP-HPLC and SDS-PAGE.
Form: Supplied as a lyophilized powder from 10mM sodium citrate pH 3.0. Reconstitute in sterile 100mM acetic acid, 0.1% BSA to a concentration 0.1mg/ml, which can then be diluted to other aqueous solutions.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. Int J Immunopathol Pharmacol 2006 Jan-Mar;19(1):67-79. 2. Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. Kidney Int 2006 Apr;69(8):1393-402. 3. TNP-470 blockage of VEGF synthesis is dependent on MAPK/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells.Biochem Biophys Res Commun 2006 Mar 3;341(1):239-44. 4. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest 2006 Jan;116(1):237-48. 5. Heterodimerization of FGF-receptor 1 and PDGF-receptor-alpha: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Blood 2006 Mar 1;107(5):1896-902. 6. Disruption of intermolecular disulfide bonds in PDGF-BB dimers by N-acetyl-L-cysteine does not prevent PDGF signaling in cultured hepatic stellate cells. Biochem Biophys Res Commun 2005 Dec 30;338(4):1711-8.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.